GlaxoSmithKline Pharmaceuticals

Price chart

Previous close

₹2,539.60

Open

₹2,551.90

Day high

₹2,755.00

Day low

₹2,547.80

Listed on NSE since 15 December 2000.

Market value

₹42,772 Cr

P/E (trailing)

37.30

EPS (trailing)

₹67.68

Price to book

22.73

Dividend yield

2.26%

Return on equity

63.9%

Debt to equity

0.02

Profit margin

27.3%

Volume today

5.92 L

Average volume

1.08 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: GlaxoSmithKline Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of GlaxoSmithKline Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: GlaxoSmithKline Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Industry

Drug Manufacturers - General

Based in

Mumbai

Employees

3,103

Company website · Profile: Yahoo Finance

No headlines name GlaxoSmithKline Pharmaceuticals in the last day or two.

• Dividend - Rs 57 Per Share

  Dividend · ex-date 29 May 2026

• Dividend - Rs 42 Per Share

  Dividend · ex-date 30 May 2025

• Interim Dividend - Rs 12 Per Share

  Dividend · ex-date 7 November 2024

• Dividend - Rs 32 Per Share

  Dividend · ex-date 31 May 2024

• Dividend - Rs 32 Per Share

  Dividend · ex-date 30 June 2023

• Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share

  Dividend · ex-date 7 July 2022 · record date 8 July 2022

• Annual General Meeting/Dividend - Rs 30 Per Share

  Dividend · ex-date 19 July 2021 · record date 20 July 2021

• Dividend - Rs 20 And Special Dividend - Rs 20 Per Share

  Dividend · ex-date 17 July 2020 · record date 20 July 2020

Source: NSE. Latest first, 8 of 20.